Lataa...
The Promise of Chimeric Antigen Receptor Engineered T cells in the Treatment of Hematologic Malignancies
Relapsed and refractory hematologic malignancies have a very poor prognosis. Chimeric antigen receptor (CAR) T cells are emerging as a powerful therapy in this setting. Early clinical trials of genetically modified T cells for the treatment of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia...
Tallennettuna:
| Julkaisussa: | Cancer J |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4742356/ https://ncbi.nlm.nih.gov/pubmed/26841014 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000166 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|